Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2024)
14 slides from Genetic Signatures's shareholder meeting presentation, Nov 20, 2024
Slide 1: Chairman's Address and CEO Presentation at Annual General Meeting
§ conetic Signatures ASX Code: GSS 20 November 2024 Chairman’s Address and CEO Presentation at Annual General Meeting Genetic Signatures Limited (ASX:GSS) is pleased to release the Annual General Meeting Chairman’s Address and CEO presentation. Chairman’s Address: Good morning, and welcome to the Ge
Slide 2: Chairman's Address (continued)
§ conetic Signatures And finally, during FY24, we raised a total of $45.9M via two capital raisings. This has provided the Company with a very solid balance sheet for growth from the launch and sale of our EasyScreen™ Gastrointestinal Parasite Detection Kit in the US, and to invest in other initiati
Slide 3: CEO Presentation
CEO Presentation 2024 Annual General Meeting 20 November 2024
Slide 4: Disclaimer
2024 – Annual General Meeting Disclaimer 20 November 2024 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company’s activities current as at
Slide 5: Introduction – Allison Rossiter - CEO
2024 – Annual General Meeting Introduction – Allison Rossiter - CEO 20 November 2024 Commenced as Genetic Signatures CEO 23 September 2024 2002 - 2024 2000 - 2002 3 3
Slide 6: Genetic Signatures — Technology Snapshot
2024 – Annual General Meeting Genetic Signatures — Technology Snapshot 20 November 2024 Genetic Signatures’ 3base® is a unique extraction technology which brings key benefits to molecular diagnostics tests: • Simplifies the genome of a sample to reduce the impact of mutations in viruses, bacteria, f
Slide 7: Genetic Signatures — Area of focus
2024 – Annual General Meeting Genetic Signatures — Area of focus 20 November 2024 Why focus on Infectious disease? • Infectious diseases are caused by viruses, bacteria, fungi and parasites, and can be transmitted through person to person, insect/animal to person or through contaminated food or wate
Slide 8: FY24 – Highlights from the year
2024 – Annual General Meeting FY24 – Highlights from the year 20 November 2024 • Revenue from operations of A$9.8M: 10.7% from EMEA, gross margin of 53% • Completed two capital raisings with net proceeds totaling $45.9M (before costs) • $15.9M Placement and Rights Issues in December 2023 • $30.0M Pl
Slide 9: Historical revenue (A$M)
2024 – Annual General Meeting Historical revenue (A$M) 20 November 2024 Return to strong quarterly revenue following TGA authorisation for supply of the modified respiratory assay in April 2024 • Total revenue of $9.8M recorded for FY24: • Q1 FY24: Revenue of $4.7M – Australian customers resumed his
Slide 10: Gastrointestinal Parasite Kit - Compelling US opportunity
2024 – Annual General Meeting Gastrointestinal Parasite Kit - Compelling US opportunity 20 November 2024 FDA clearance to market Genetic Signatures’ EasyScreenTM Gastrointestinal Parasite Detection Kit in the US received in June 2024 The product addresses a well-recognised, poorly-met clinical need
Slide 11: Relevant for all key customer segments
2024 – Annual General Meeting Relevant for all key customer segments 20 November 2024 Target GI parasite testing Potential TAM Share of targeted 2.2M segments requirements = 5.5M tests tests by segment High volume Large commercial 1.6 M 50% LabCorp / Quest = >1500 tests / day reference labs Others ~
Slide 12: Commercial sales in the US imminent
2024 – Annual General Meeting Commercial sales in the US imminent 20 November 2024 ✓ Customer experience sites well-advanced in internal review process with several at the final contract stage ✓ Established a strong sales pipeline with >60 customer sites at various stages of the evaluation and sales
Slide 13: For the year ahead
For the year ahead 2024 – Annual General Meeting 20 November 2024 • Our Customers • Several customer experience sites at final contract stage • A strong sales pipeline, incl major US reference labs • New signed contracts in UK • Evaluations underway in UK and Germany • Implementing sales excellence
Slide 14: Contact Us
Contact Us Allison Rossiter Chief Executive Officer E: allison.rossiter@geneticsignatures.com P: +61 (02) 9870 7580 Karl Pechmann Chief Financial & Operating Officer & Company Secretary E: karl.pechmann@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 12
Genetic Signatures — Shareholder Meeting (November 2024) on 6ix